Faron’s Traumakine Flops In Phase III

 
• By Lucie Ellis-Taitt

Faron Pharmaceuticals’ stock has plummeted more than 80% on the news its lead drug failed in a Phase III trial – the company will now shift its focus to an investigational cancer therapy, but this is yet to enter the clinic.

Tower
Faron's stock tumbles after lead drug crashes down in Phase III • Source: Shutterstock

More from Strategy

More from Business